Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EINSTEIN-Jr Phase 2
NCT01684423Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2013
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of rivaroxaban in venous thrombosis (5 arms), sponsored by Bayer. Primary endpoint: Number of Subjects With Major and Clinically Relevant Non-Major Bleeding Events at 30 days. Started Feb 2013; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thrombosis
Beyond the preview
Go deeper on NCT01684423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01684423.